Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders
- 11 February 2020
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 237 (5) , 1521-1532
Abstract
Rationale The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. Objectives This paper examined subjective experiences of microdosing psychedelics to improve mental health or to cease or reduce substance use, and examined sociodemographic and other covariates of perceived improvements in mental health that individuals attributed to microdosing. Methods An international online survey was conducted in 2018 and examined people’s experiences of using psychedelics for self-reported therapeutic or enhancement purposes. This paper focuses on 1102 respondents who reported current or past experience of psychedelic microdosing. Results Twenty-one percent of respondents reported primarily microdosing as a therapy for depression, 7% for anxiety, 9% for other mental disorders and 2% for substance use cessation or reduction. Forty-four percent of respondents perceived that their mental health was “much better” as a consequence of microdosing. In a multivariate analysis, perceived improvements in mental health from microdosing were associated with a range of variables including gender, education, microdosing duration and motivations, and recent use of larger psychedelic doses. Conclusions Given the promising findings of clinical trials of standard psychedelic doses as mental health therapies, clinical microdosing research is needed to determine its potential role in psychiatric treatment, and ongoing social research to better understand the use of microdosing as self-managed mental health and substance use therapies.Keywords
Funding Information
- Alexander von Humboldt-Stiftung
This publication has 51 references indexed in Scilit:
- Solving the problem of non‐attendance in substance abuse servicesDrug and Alcohol Review, 2014
- Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening DiseasesJournal of Nervous & Mental Disease, 2014
- Estimating treatment rates for mental disorders in AustraliaAustralian Health Review, 2013
- Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010The Lancet, 2013
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsJournal of Psychopharmacology, 2012
- A meta-analysis of depression severity and cognitive functionJournal of Affective Disorders, 2009
- A review on cognitive impairments in depressive and anxiety disorders with a focus on young adultsJournal of Affective Disorders, 2008
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- Patient adherence in the treatment of depressionThe British Journal of Psychiatry, 2002
- The PHQ-9Journal of General Internal Medicine, 2001